Back to discover
Drug

Lirilumab

In clinical development
ClassKiller cell immunoglobulin-like receptor 2DL1 inhibitorEmerging researchEarly-to-mid development
RxNorm1967731ChEMBLCHEMBL2109500UNIIS9XDI9W918
1
Research papers
2
Active clinical trials
3
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Clinical trial2026-07-10Results expected Q1 2031 · ClinicalTrials.gov

Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies

Clinical trial2025-10-22Results posted · ClinicalTrials.gov

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck

Clinical trial2025-06-18Results posted · ClinicalTrials.gov

Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab.

Research2024-01-07Scientific reports

A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

Clinical trial2023-02-02Results posted · ClinicalTrials.gov

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

Clinical trial2021-01-29Terminated · ClinicalTrials.gov

A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination With Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab, BMS-734016) in Advanced and/or Metastatic Solid Tumors

Clinical trial2020-08-06Completed · ClinicalTrials.gov

Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Clinical trial2020-05-28Results posted · ClinicalTrials.gov

Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Clinical trial2019-01-30Terminated · ClinicalTrials.gov

An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia

Clinical trial2018-07-12Terminated · ClinicalTrials.gov

A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Clinical trial2017-10-10Completed · ClinicalTrials.gov

A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors

Clinical trial2015-04-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Lirilumab
RxNorm CUI
1967731
ChEMBL ID
CHEMBL2109500
UNII
S9XDI9W918
Primary mechanism
Killer cell immunoglobulin-like receptor 2DL1 inhibitor

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Killer cell immunoglobulin-like receptor 2DL1
KIR2DL1 · P43626
INHIBITORKiller cell immunoglobulin-like receptor 2DL1 inhibitor
Killer cell immunoglobulin-like receptor 2DL2
KIR2DL2 · P43627
INHIBITORKiller cell immunoglobulin-like receptor 2DL2 inhibitor
Killer cell immunoglobulin-like receptor 2DL3
KIR2DL3 · P43628
INHIBITORKiller cell immunoglobulin-like receptor 2DL3 inhibitor

Clinical trials

11 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
11
registered trials across all phases
LATEST COMPLETION 2024
2
Active studies
1
Recruiting
6
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 11
Phase 13Phase 1 / 24Phase 24

Recent completions

Trials that read out recently, adding to the completed evidence base.

Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies

CompletedPH I/IIBristol-Myers Squibbn=3202024

A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination With Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab, BMS-734016) in Advanced and/or Metastatic Solid Tumors

CompletedPH IBristol-Myers Squibbn=102020

A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

CompletedPH I/IIBristol-Myers Squibbn=3372019

Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

CompletedPH IIM.D. Anderson Cancer Centern=72019

A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

CompletedPH IBristol-Myers Squibbn=442017

A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors

CompletedPH IBristol-Myers Squibbn=222015

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Amino Acids1Immune Checkpoint Inhibitors1
Journals, researchers & institutions
Top journals
  • Scientific reports1
Leading researchers
  • DuBois RM1
  • Harpell NM1
  • Lorig-Roach N1
Leading institutions
free-text, unnormalised
  • University of California Santa Cruz1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Amino Acids

Frequently co-studied with Lirilumab in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials